



Ordering

Product Name	Number of Samples	Catalog Number
QuantideX [®] NGS RNA Lung Cancer Kit*	48	49602
QuantideX [®] NGS RNA Lung Cancer Kit*	192	49603

*For Research Use Only. Not for use in diagnostic procedures.

Learn More

For more information on the QuantideX NGS RNA Lung Cancer Kit* and other QuantideX NGS products, please visit our oncology product information page at asuragen.com/portfolio/oncology.

QuantideX[®]

NGS RNA Lung Cancer Kit*



Asuragen, Inc.
2150 Woodward Street, Suite 100
Austin TX 78744
asuragen.com

QuantideX®

NGS RNA Lung Cancer Kit*



The QuantideX® NGS RNA Lung Cancer Kit* is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and expression frequently observed in non-small cell lung cancer (NSCLC). Leveraging our proprietary NGS-in-a-Box™ workflow and *Sample-Aware*™ bioinformatics quality control solutions, this kit offers a simple, sensitive, and reliable NGS assay for routine investigation of NSCLC samples.

- ▶ Unique NGS-in-a-Box™ Solution
- ▶ Best-in-Class Workflow
- ▶ *Sample-Aware*™ Quality Control

REDUCED COMPLEXITY

- Single assay for broad range of important NSCLC fusion targets
- End-to-end, kitted solution
- Fully integrated data analysis pipeline

OPTIMIZED WORKFLOW

- Reduced labor vs. currently available commercial kits (>50% Improvement)
- Improved TAT enables higher throughput
- Common workflow across portfolio streamlines training and implementation

QUALITY PERFORMANCE

- Highly reproducible, sensitive detection of RNA-based fusions
- Low input (~20 ng) of RNA from FFPE
- *Sample-Aware*™ bioinformatics analysis and sample quality control

Broad Range of Important NSCLC Fusion Targets†


3' FUSION GENES	# OF FUSIONS	3' / 5' IMBALANCE	EXON SKIPPING EVENT
ALK	53	ALK	MET e13:e14
ROS1	22	ROS1	MET e14:e15
RET	12	RET	MET e13:e15
FGFR3	7	NTRK1	
NTRK1	4		
NTRK3	3		
NRG1	2	mRNA EXPRESSION TARGETS	
FGFR1	1	ABCB1	ESR1
FGFR2	1	BRCA1	FGFR1
MBIP	1	CD274*	FGFR2
PDGFRA	1	CDKN2A	IFNGR
		CTLA4	ISG15
		ERCC1	MET
			TDP1
			Endo. Controls
			MSLN
			TERT
			PDCD1
			TLE3
			PDCD1LG2**
			TOP1
			PTEN
			TUBB3
			TYMS

- All Major Fusion Genes
- 107 Known & Relevant NSCLC Fusions
- 3' / 5' Imbalance for Novel Rearrangements
- MET Exon Skipping Events
- mRNA Expression Targets

* PD-L1 ** PD-L2



†Content sourced from: NCCN Guidelines, customer needs, COSMIC, Clinicaltrials.gov, publications & other databases.

Reduced Labor vs. Commercially Available Kits



Highly Sensitive Detection with Unique Quality Control

Combining unique primer design with proprietary full process *Sample-Aware*™ QC, enables high sensitivity detection of known fusion-positive EML4-ALK synthetic control in as low as 5 copies of TNA (left). MET ex14 skipping events (e13/e14; e14/e15; e13/e15) are detected in the assay (right).



Sample-Aware™ Bioinformatics

Our software solutions combine machine-learning algorithms with integrated QC capabilities and run metrics to enable automatic and accurate result calling. These capabilities ensure constant result quality monitoring and reduce false positive results while highlighting false negative risk.